Rabi Hanna, Pediatric Blood and Marrow Transplant Program Director, and Chairman at the Department of Pediatric Hematology-Oncology and BMT at Cleveland Clinic, shared a post on X:
“Thank you Amer Zeidan for outstanding talk about immune checkpoint inhibitors in MDS at precision oncology symposium and future directions.
Remember that allogenic HSCT works innMDS/AML which proves myeloid malignancy is immunogenic and amenable to ‘immunotherapy’.”
More posts featuring Rabi Hanna.
